Cargando…

Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer

A phase II study of cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony stimulating factor (rhG-CSF) support was conducted in previously untreated patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). Between June 1998 and August 2001, 50 patients were regist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujita, A, Ohkubo, T, Hoshino, H, Takabatake, H, Tagaki, S, Sekine, K, Abe, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376953/ https://www.ncbi.nlm.nih.gov/pubmed/12966417 http://dx.doi.org/10.1038/sj.bjc.6601230

Ejemplares similares

Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients
por: Jiang, Yantao, et al.
Publicado: (2023)

Long-term safety of filgrastim (rhG-CSF) administration
por: Confer, Dennis L, et al.
Publicado: (2007)

rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy
por: Wang, Yong, et al.
Publicado: (2022)

Antitumoral effect of maintained neutrophilia induced by rhG-CSF in a murine model of pancreatic cancer
por: Brú, A., et al.
Publicado: (2019)

Radioprotective effects of Sipunculus nudus L. polysaccharide combined with WR-2721, rhIL-11 and rhG-CSF on radiation-injured mice
por: Jiang, Shuqi, et al.
Publicado: (2015)

Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research
por: Lasagna, Angioletta, et al.
Publicado: (2021)

Efficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer
por: Li, Weiwei, et al.
Publicado: (2023)

PEG‐rhG‐CSF for prophylaxis of neutropenia after chemotherapy in patients with non–small cell lung cancer: A multicenter, prospective, randomized study
por: Sun, Xu‐Sheng, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutropenia in Women With Breast Cancer in China: Results Based on Real-World Data
por: Zhao, Jie, et al.
Publicado: (2022)

A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer
por: Zou, Dongling, et al.
Publicado: (2021)

PEG-rhG-CSF应用于DA-EPOCH-R方案一线治疗的弥漫大B细胞淋巴瘤的可行性研究
Publicado: (2020)

Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial
por: Gao, Lei, et al.
Publicado: (2020)

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis
por: Huang, Junting, et al.
Publicado: (2023)

The rhg1‐a (Rhg1 low‐copy) nematode resistance source harbors a copia‐family retrotransposon within the Rhg1‐encoded α‐SNAP gene
por: Bayless, Adam M., et al.
Publicado: (2019)

Mapping soybean rhg2 locus, which confers resistance to soybean cyst nematode race 1 in combination with rhg1 and Rhg4 derived from PI 84751
por: Suzuki, Chika, et al.
Publicado: (2020)

Genetic relationships of soybean cyst nematode resistance originated in Gedenshirazu and PI84751 on Rhg1 and Rhg4 loci
por: Suzuki, Chika, et al.
Publicado: (2012)

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
por: Sekine, I, et al.
Publicado: (2008)

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
por: Bokemeyer, C., et al.
Publicado: (1996)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Epistatic interaction between Rhg1-a and Rhg2 in PI 90763 confers resistance to virulent soybean cyst nematode populations
por: Basnet, Pawan, et al.
Publicado: (2022)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

PB2199: A REAL WORLD STUDY OF PEG-RHG-CSF ON HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Xu, J., et al.
Publicado: (2022)

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
por: Wachters, F M, et al.
Publicado: (2005)

Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
por: Michel, P, et al.
Publicado: (2006)

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
por: Sculier, J-P, et al.
Publicado: (2000)

Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
por: Kosmas, C, et al.
Publicado: (2009)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

Whole‐genome re‐sequencing reveals the impact of the interaction of copy number variants of the rhg1 and Rhg4 genes on broad‐based resistance to soybean cyst nematode
por: Patil, Gunvant B., et al.
Publicado: (2019)

Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis
por: Yang, Xue-Qin, et al.
Publicado: (2015)

Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor
por: Kurobe, Masahiro, et al.
Publicado: (2014)

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
por: Sekine, I, et al.
Publicado: (2003)

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
por: Goto, K, et al.
Publicado: (2004)

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
por: OZKAYA, SEVKET, et al.
Publicado: (2012)

The retarded hair growth (rhg) mutation in mice is an allele of ornithine aminotransferase (Oat)
por: Bisaillon, Jason J., et al.
Publicado: (2014)

LncmiRHG-MIR100HG: A new budding star in cancer
por: Wu, Yingnan, et al.
Publicado: (2022)

Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma
por: Scandurra, Giuseppa, et al.
Publicado: (2015)

Ogilvie Syndrome in a Refractory Germ Cell Tumor Treated with Vinblastine, Ifosfamide and Cisplatin Regimen
por: Varayathu, Hrishi, et al.
Publicado: (2020)

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
por: von Amsberg, Gunhild, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rgjfdr7vgf73ig6pkj9crer7tv